Residence in/travel to a country/area or territory with local transmission, or close contact with a confirmed or probable case of COVID-19, in the 14 days prior to symptom onset.
Signs and symptoms are similar so it may be difficult to differentiate between the conditions clinically.
The situation is evolving rapidly; see our COVID-19 topic for further information.
Real-time reverse transcription polymerase chain reaction (RT-PCR): positive for SARS-CoV-2 RNA.
It is not possible to differentiate COVID-19 from other causes of pneumonia on chest imaging.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Patients have lower incidence of comorbidities compared with MERS.
Clinical features are similar; however, patients are less likely to present with haemoptysis (1% of patients with SARS) or dyspnoea (42% of patients with SARS).[8]
Usually less aggressive than MERS as reflected by the lower mortality rate.[113]
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Seasonal outbreak during winter.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
RT-PCR: negative for MERS coronavirus (MERS-CoV) RNA.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Seasonal outbreak during winter.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
RT-PCR: positive for influenza A or B viral RNA.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Close contact with infected birds (e.g., farmer or visitor to a live market in endemic areas) or living in an area where avian influenza is endemic.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
RT-PCR: positive for H5N1 viral RNA.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Close contact with infected birds (e.g., farmer or visitor to a live market in endemic areas) or living in an area where avian influenza is endemic. Up until now, the epidemic has been geographically focused in China.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
RT-PCR: positive for H7-specific viral RNA.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Common cause of lower respiratory tract infection in children <1 year of age.
Seasonal outbreak during winter.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
RT-PCR: positive for RSV RNA.
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
Blood or sputum culture, or multiplex RT-PCR testing: positive for causative organism (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Moraxella catarrhalis).
Lack of travel history to or from the Middle East (or country where there is an ongoing outbreak) in the preceding 14 days.
No close contact with a symptomatic traveller from the Middle East or a suspected or confirmed case of MERS in the preceding 14 days.
Differentiating MERS from community-acquired respiratory tract infections is not possible from signs and symptoms.
Unlikely to cause serious illness in young, healthy patients.
Nasopharyngeal virus culture or RT-PCR: positive for causative organism (e.g., parainfluenza viruses, adenoviruses, rhinoviruses, enteroviruses, human metapneumovirus) or viral RNA.
Use of this content is subject to our disclaimer